MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, trading under the ticker HLXA, is a clinical-stage biopharmaceutical company focused on novel nanobody-based therapies for inflammatory diseases, including hidradenitis suppurativa and psoriatic arthritis. The company entered public markets through a SPAC structure in 2021, operating within the healthcare and life sciences sector. In December 2021, the company filed a 10-Q/A, an amended quarterly report, with accession number 0001213900-21-065247, reflecting disclosures during its de-SPAC transition period. MoonLake subsequently rebranded its Nasdaq listing to the ticker MLTX following completion of its merger. For the full filing history, sponsor details, and deal metrics on HLXA, sign up for complete data access at SpacDesk.